Nelarabine

證據等級: L5

預測適應症: 1 個

Nelarabine: From T-cell Acute Lymphoblastic Leukemia/Lymphoma to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Nelarabine (DrugBank DB01280) is a purine nucleoside analogue prodrug internationally approved for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma; it is not currently marketed in Finland. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis, with a prediction score of 99.43%, but no supporting clinical trials or literature have been identified to date.

Quick Overview

Item	Content
Original Indication	T-cell acute lymphoblastic leukemia (T-ALL) / T-cell lymphoblastic lymphoma (T-LBL) — per known international approval; not present in Finland licensing records
Predicted New Indication	Relapsing-remitting multiple sclerosis
TxGNN Prediction Score	99.43%
Evidence Level	L5
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (flagged as a High-severity data gap). Based on known pharmacological information, nelarabine is a prodrug of ara-G (9-β-D-arabinofuranosylguanine), a deoxyguanosine analogue. It is dephosphorylated to ara-G, taken up preferentially by T-lymphoblasts, and phosphorylated intracellularly to the active triphosphate ara-GTP, which is incorporated into DNA and inhibits DNA synthesis, leading to selective T-cell death. It belongs to the purine nucleoside analogue (antimetabolite) class, and its efficacy in T-cell malignancies has been established through international approval.

Mechanistically, purine nucleoside analogues as a class are already clinically validated in autoimmune neurology: cladribine, a related purine analogue, is an approved disease-modifying therapy for relapsing-remitting multiple sclerosis precisely because of its selective depletion of circulating lymphocytes. Given nelarabine's comparable lymphocyte-selective cytotoxic mechanism, a repurposing hypothesis toward an immune-mediated, lymphocyte-driven disease such as RRMS is biologically plausible. However, this rationale is currently mechanistic/analogical only — it is not yet supported by any disease-specific trial or literature evidence.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Nelarabine currently has no marketing authorization in Finland (0 licenses on record); no product/dosage form data is available for this candidate.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Purine nucleoside analogue / antimetabolite)
Myelosuppression Risk	High — known class effect of purine analogues (neutropenia, thrombocytopenia, anemia commonly reported in published prescribing information)
Emetogenicity Classification	Moderate
Monitoring Items	CBC with differential, neurological examination (peripheral and central neurotoxicity is a recognized class concern), renal and hepatic function
Handling Protection	Yes — standard cytotoxic drug handling precautions apply

Note: TFDA package insert data is a Blocking data gap; the above reflects general knowledge of the drug class, not verified local labeling. Confirm against official prescribing information before clinical use.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests solely on a TxGNN model score (L5 evidence) — no clinical trials, ICTRP registrations, or literature support this indication, and the drug is not currently marketed in Finland. The mechanistic rationale is analogical (based on a related drug class), not direct evidence.

To proceed, the following is needed:

TFDA package insert / official prescribing information (currently Blocking gap)
Confirmed DrugBank MOA data
Any preclinical or case-level evidence linking nelarabine to demyelinating/autoimmune disease
Formal safety profile: contraindications, key warnings, DDI data
Periodic re-query of clinicaltrials.gov, ICTRP, and PubMed as this is a novel, unstudied indication pairing
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.